Ruxolitinib for Polycythemia Vera Intolerant or Resistant to Hydroxyurea

home / between-the-lines / ruxolitinib-for-polycythemia-vera-intolerant-or-resistant-to-hydroxyurea

Timothy Mok, PharmD, BCPS, BCOP, and Gabriela Hobbs, MD, review findings from the MAJIC-PV study and offer insights on the evolving treatment of patients with polycythemia vera who have hydroxyurea intolerance or resistance.

© 2024 MJH Life Sciences

All rights reserved.